Imperial and Seattle sign agreement
Seattle Genetics has entered into a licence agreement with Imperial College Innovations Limited, the technology transfer company of Imperial College London, for exclusive rights to a novel monoclonal antibody targeting a cell surface tumour-associated antigen.
Seattle Genetics has entered into a licence agreement with Imperial College Innovations Limited, the technology transfer company of Imperial College London, for exclusive rights to a novel monoclonal antibody targeting a cell surface tumour-associated antigen.
Seattle Genetics plans to evaluate the therapeutic potential of the antibody against a variety of cancers, including haematologic malignancies and solid tumours such as breast, colon and bladder cancer.
'This agreement provides us with a valuable addition to our research pipeline of antibody-based therapeutic candidates,' commented Dr Douglas Williams, chief scientific officer and executive vice president, r&d, at Seattle Genetics. 'This monoclonal antibody has shown promising activity in preclinical models of cancer, and the issued patents provide us with a strong intellectual property position. We plan to ex-plore the therapeutic potential of the antibody on its own and as an antibody-drug conjugate utilizing our industry-leading ADC technology.'
Under the agreement, Seattle Genetics has obtained an exclusive license to two issued US patents covering composition of matter of the designated antigen and methods of use of monoclonal antibodies targeting the antigen, as well as cell lines and associated intellectual property rights. Seattle Genetics has development, manufacturing and worldwide commercialisation rights to products developed under the licence agreement. Imperial College Innovations will receive an upfront fee, progress-dependent milestone payments and royalties on net sales of any resulting products. Financial terms were not disclosed.